Phiona E. Namale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Phiona E. Namale has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Alexis Maseko
Department of Medicine, University of Cape Town , Cape Town
3 shared publicationsAbulele Bekiswa
Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
2 shared publicationsAmanda Jackson
Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
2 shared publicationsAndrew Hill
LSE Health, London School of Economics and Political Science, London, UK
2 shared publicationsArifa Parker
Department of Medicine, Stellenbosch University, Stellenbosch, South Africa
2 shared publicationsAshleigh Barnes
Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Relative Diagnostic Yield of Tests for Disseminated Tuberculosis Among Inpatients With Human Immunodeficiency Virus
Background: Disseminated tuberculosis (TB) is a major cause of morbidity and mortality among people with human immunodeficiency virus (HIV-1). Early diagnosis is critical, yet the optimal diagnostic strategy remains uncertain. We aimed to describe the relative diagnostic yield of tests for disseminated TB and to explore associations between test results and patient characteristics. Methods: We conducted a cross-sectional study nested within the screening population of a clinical trial of participants with HIV-associated disseminated TB, who were identified by at least 1 positive result from urine lipoarabinomannan (uLAM), urine Xpert MTB/RIF Ultra (uXPU), TB blood culture, or blood Xpert Ultra (blXPU). Diagnostic yield was defined as the proportion positive by that test among all participants diagnosed with disseminated TB. Results: Among the 426 participants, 56% were female, median age was 35 years, and median CD4 count was 39 cells/μL. Advanced HIV (defined as CD4 count <200 cells/μL) was present in 385 (90%), and 36 (8%) participants had an HIV RNA measurement <50 copies/mL. Diagnostic yield was higher for uXPU (82%) than uLAM (68%), blXPU (30%), and TB blood culture (24%). The incremental diagnostic yield from performing uXPU following uLAM was 29.6%. There was minimal incremental yield from performing either TB blood culture or blXPU after both uLAM and uXPU. Diagnostic yield declined with increasing CD4 count for all assays except uXPU. Conclusions: Urine LAM and uXPU provide complementary diagnostic yields for disseminated TB. The high yield of uXPU supports its inclusion alongside uLAM in TB diagnostic algorithms among inpatients with HIV.
- 31 October 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (11)
Open AccessRelative Diagnostic Yield of Tests for Disseminated Tuberculosis Among Inpatients With Human Immunodeficiency Virus
Background: Disseminated tuberculosis (TB) is a major cause of morbidity and mortality among people with human immunodeficiency virus (HIV-1). Early diagnosis is critical, yet the optimal diagnostic strategy remains uncertain. We aimed to describe the relative diagnostic yield of tests for disseminated TB and to explore associations between test results and patient characteristics. Methods: We conducted a cross-sectional study nested within the screening population of a clinical trial of participants with HIV-associated disseminated TB, who were identified by at least 1 positive result from urine lipoarabinomannan (uLAM), urine Xpert MTB/RIF Ultra (uXPU), TB blood culture, or blood Xpert Ultra (blXPU). Diagnostic yield was defined as the proportion positive by that test among all participants diagnosed with disseminated TB. Results: Among the 426 participants, 56% were female, median age was 35 years, and median CD4 count was 39 cells/μL. Advanced HIV (defined as CD4 count <200 cells/μL) was present in 385 (90%), and 36 (8%) participants had an HIV RNA measurement <50 copies/mL. Diagnostic yield was higher for uXPU (82%) than uLAM (68%), blXPU (30%), and TB blood culture (24%). The incremental diagnostic yield from performing uXPU following uLAM was 29.6%. There was minimal incremental yield from performing either TB blood culture or blXPU after both uLAM and uXPU. Diagnostic yield declined with increasing CD4 count for all assays except uXPU. Conclusions: Urine LAM and uXPU provide complementary diagnostic yields for disseminated TB. The high yield of uXPU supports its inclusion alongside uLAM in TB diagnostic algorithms among inpatients with HIV.
- Open Access
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis
Background: Treatment response biomarkers are needed in the care of patients hospitalised with HIV-associated tuberculosis (TB). Objectives: We describe the changes in bacillary load during early treatment using quantitative and semi-quantitative measures of Mycobacterium tuberculosis in blood and urine. Method: We collected serial blood and urine samples at multiple timepoints in consenting adult patients with HIV and positive urine lipoarabinomannan (LAM), admitted to Mitchells Plain Hospital, Cape Town. Blood and urine Xpert Ultra, mycobacterial blood culture and urine LAM were performed. Survival analysis and mixed-effects modelling were used to determine time to a negative test, and to give the predicted probability of a positive test at the different timepoints. Results: Sixteen participants, predominantly male (63%), with median age 39 years (interquartile range [IQR] 36–43), and CD4 count 27 cells/mm3 (IQR 8–83) were included. At day 14, urine LAM, urine Xpert Ultra and blood Xpert Ultra remained positive in between 75% and 86% of the participants. A mixed-effects model predicted a decline in ordinal values of urine Xpert Ultra (cycle threshold), blood Xpert Ultra (cycle threshold) and blood culture (time-to-positivity) in response to anti-TB treatment. Conversely, urine LAM grade intensity increased over the 14 days. Conclusion: M. tuberculosis DNA was detectable in urine and blood in decreasing quantity up to 14 days of standard treatment in patients with HIV-associated TB. Urine Alere LAM showed an increasing grade intensity during this period. Further research in larger groups and extended periods are needed to assess relation to clinical outcomes.
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
Open AccessBlood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis
Background: Treatment response biomarkers are needed in the care of patients hospitalised with HIV-associated tuberculosis (TB). Objectives: We describe the changes in bacillary load during early treatment using quantitative and semi-quantitative measures of Mycobacterium tuberculosis in blood and urine. Method: We collected serial blood and urine samples at multiple timepoints in consenting adult patients with HIV and positive urine lipoarabinomannan (LAM), admitted to Mitchells Plain Hospital, Cape Town. Blood and urine Xpert Ultra, mycobacterial blood culture and urine LAM were performed. Survival analysis and mixed-effects modelling were used to determine time to a negative test, and to give the predicted probability of a positive test at the different timepoints. Results: Sixteen participants, predominantly male (63%), with median age 39 years (interquartile range [IQR] 36–43), and CD4 count 27 cells/mm3 (IQR 8–83) were included. At day 14, urine LAM, urine Xpert Ultra and blood Xpert Ultra remained positive in between 75% and 86% of the participants. A mixed-effects model predicted a decline in ordinal values of urine Xpert Ultra (cycle threshold), blood Xpert Ultra (cycle threshold) and blood culture (time-to-positivity) in response to anti-TB treatment. Conversely, urine LAM grade intensity increased over the 14 days. Conclusion: M. tuberculosis DNA was detectable in urine and blood in decreasing quantity up to 14 days of standard treatment in patients with HIV-associated TB. Urine Alere LAM showed an increasing grade intensity during this period. Further research in larger groups and extended periods are needed to assess relation to clinical outcomes.
- Open Access
- 8 May 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-23
Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial
Background: HIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalised at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.Methods: This is a phase III randomised controlled superiority trial, evaluating two interventions in a 2 × 2 factorial design: (1) high dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment and (2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.Discussion: Disseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice.Trial registration: ClinicalTrials.gov NCT04951986. Registered on 7 July 2021https://clinicaltrials.gov/study/NCT04951986
- 8 May 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-23
Open AccessTesting novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial
Background: HIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalised at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.Methods: This is a phase III randomised controlled superiority trial, evaluating two interventions in a 2 × 2 factorial design: (1) high dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment and (2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.Discussion: Disseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice.Trial registration: ClinicalTrials.gov NCT04951986. Registered on 7 July 2021https://clinicaltrials.gov/study/NCT04951986
- Open Access
- 1 April 2024
- Published by Springer Nature in Research Square
Testing Novel Strategies for Patients Hospitalized with HIV-associated Disseminated Tuberculosis (NewStrat-TB): Protocol for a Randomised Controlled Trial
BackgroundHIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalized at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.MethodsThis is a phase III randomised controlled superiority trial, evaluating two interventions in a 2x2 factorial design: 1) high dose rifampicin (35mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment; and 2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra, or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.DiscussionDisseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice. ClinicalTrials.gov ID: NCT04951986. Trial registration Registered on 7 July 2021 https://clinicaltrials.gov/study/NCT04951986
- 1 April 2024
- Published by Springer Nature in Research Square
Open AccessTesting Novel Strategies for Patients Hospitalized with HIV-associated Disseminated Tuberculosis (NewStrat-TB): Protocol for a Randomised Controlled Trial
BackgroundHIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalized at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB.MethodsThis is a phase III randomised controlled superiority trial, evaluating two interventions in a 2x2 factorial design: 1) high dose rifampicin (35mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment; and 2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra, or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events.DiscussionDisseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduce mortality. If found to be safe and effective, the interventions being evaluated in this trial could be easily implemented in clinical practice. ClinicalTrials.gov ID: NCT04951986. Trial registration Registered on 7 July 2021 https://clinicaltrials.gov/study/NCT04951986
- Open Access
- 22 November 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 9
Adherence to a care bundle for Staphylococcus aureus bacteraemia: A retrospective cohort study
Background: Staphylococcus aureus bacteraemia is associated with high hospital mortality. Improvements in outcome have been described with standardised bundles of care. Objectives: To study the adherence of a standardised bundle of care (BOC) recommendations using a consultation pro forma, for all patients admitted with S. aureus bacteraemia to Groote Schuur Hospital over a year. The study further aimed to describe the 90-day mortality in these patients and to assess for an association between adherence to the bundle of care and outcome. Method: A retrospective audit of all unsolicited infectious disease consultations for patients with S. aureus bacteraemia admitted to Groote Schuur Hospital during 2018. Adherence to recommendations of a standard bundle of care was audited. Results: A total of 86 patients were included in the study: 61 (71%) with hospital-associated infection and 25 (29%) with community-associated infection. Over 80% of adherence to treatment recommendations was achieved regarding antibiotic (including vancomycin) usage, source control and use of echocardiography as required. In-hospital mortality was 16%, while the overall 90-day mortality was 18%, with only age as an independent predictor of mortality. No association between adherence to the bundle of care and outcome was found. Conclusion: Adherence to a simple, structured bundle of care was good when using standardised pro forma as communication tools for advice and a structured antibiotic chart for vancomycin administration. Although adherence was not associated with outcome, the overall mortality for S. aureus bacteraemia was improving in the institution under study. Contribution: Our findings support feasibility and ongoing use of bundles of care for S. aureus bacteraemia in similar settings.
- 22 November 2022
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 37 (1) , 9
Open AccessAdherence to a care bundle for Staphylococcus aureus bacteraemia: A retrospective cohort study
Background: Staphylococcus aureus bacteraemia is associated with high hospital mortality. Improvements in outcome have been described with standardised bundles of care. Objectives: To study the adherence of a standardised bundle of care (BOC) recommendations using a consultation pro forma, for all patients admitted with S. aureus bacteraemia to Groote Schuur Hospital over a year. The study further aimed to describe the 90-day mortality in these patients and to assess for an association between adherence to the bundle of care and outcome. Method: A retrospective audit of all unsolicited infectious disease consultations for patients with S. aureus bacteraemia admitted to Groote Schuur Hospital during 2018. Adherence to recommendations of a standard bundle of care was audited. Results: A total of 86 patients were included in the study: 61 (71%) with hospital-associated infection and 25 (29%) with community-associated infection. Over 80% of adherence to treatment recommendations was achieved regarding antibiotic (including vancomycin) usage, source control and use of echocardiography as required. In-hospital mortality was 16%, while the overall 90-day mortality was 18%, with only age as an independent predictor of mortality. No association between adherence to the bundle of care and outcome was found. Conclusion: Adherence to a simple, structured bundle of care was good when using standardised pro forma as communication tools for advice and a structured antibiotic chart for vancomycin administration. Although adherence was not associated with outcome, the overall mortality for S. aureus bacteraemia was improving in the institution under study. Contribution: Our findings support feasibility and ongoing use of bundles of care for S. aureus bacteraemia in similar settings.